{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:04:47Z","timestamp":1790258687459,"version":"4.1.0"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Natural Science Foundation of Xinjiang Uygur Autonomous Region","award":["2025D01B23"],"award-info":[{"award-number":["2025D01B23"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474264 and 82174170"],"award-info":[{"award-number":["82474264 and 82174170"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-026-09204-z","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:41:48Z","timestamp":1790257308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Different Inflammatory Phenotypes and Immune Endotypes Drive Disease Heterogeneity in Asthma and COPD"],"prefix":"10.1007","volume":"69","author":[{"given":"Cong","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaomin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xidan","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maimaititusun","family":"Yalikun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingcheng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"9204_CR1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nm.2678","volume":"18","author":"SE Wenzel","year":"2012","unstructured":"Wenzel SE (2012) Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 18:716\u2013725. https:\/\/doi.org\/10.1038\/nm.2678","journal-title":"Nat Med"},{"key":"9204_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1465-9921-11-122","volume":"11","author":"A Agusti","year":"2010","unstructured":"Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA et al (2010) Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 11:122. https:\/\/doi.org\/10.1186\/1465-9921-11-122","journal-title":"Respir Res"},{"key":"9204_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jaci.2010.11.037","volume":"127","author":"J Lotvall","year":"2011","unstructured":"Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A et al (2011) Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 127:355\u2013360. https:\/\/doi.org\/10.1016\/j.jaci.2010.11.037","journal-title":"J Allergy Clin Immunol"},{"key":"9204_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri3786","volume":"15","author":"JV Fahy","year":"2015","unstructured":"Fahy JV (2015) Type 2 inflammation in asthma\u2013present in most, absent in many. Nat Rev Immunol 15:57\u201365. https:\/\/doi.org\/10.1038\/nri3786","journal-title":"Nat Rev Immunol"},{"key":"9204_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jaci.2016.05.011","volume":"138","author":"PJ Barnes","year":"2016","unstructured":"Barnes PJ (2016) Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 138:16\u201327. https:\/\/doi.org\/10.1016\/j.jaci.2016.05.011","journal-title":"J Allergy Clin Immunol"},{"key":"9204_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(17)30217-5","volume":"5","author":"M Bafadhel","year":"2017","unstructured":"Bafadhel M, Pavord ID, Russell REK (2017) Eosinophils in COPD: just another biomarker? Lancet Respir Med 5:747\u2013759. https:\/\/doi.org\/10.1016\/S2213-2600(17)30217-5","journal-title":"Lancet Respir Med"},{"key":"9204_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41392-026-02853-8","volume":"11","author":"C Xie","year":"2026","unstructured":"Xie C, Wei Y, Su C, Yalikun M, Chu Y, Yu H et al (2026) Mechanisms and therapeutic strategies of asthma: from bench to bedside. Signal Transduct Target Ther 11:317. https:\/\/doi.org\/10.1038\/s41392-026-02853-8","journal-title":"Signal Transduct Target Ther"},{"key":"9204_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2019.05.031","volume":"144","author":"R Kaur","year":"2019","unstructured":"Kaur R, Chupp G (2019) Phenotypes and endotypes of adult asthma: Moving toward precision medicine. J Allergy Clin Immunol 144:1\u201312. https:\/\/doi.org\/10.1016\/j.jaci.2019.05.031","journal-title":"J Allergy Clin Immunol"},{"key":"9204_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1183\/13993003.01359-2015","volume":"47","author":"A Agusti","year":"2016","unstructured":"Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S et al (2016) Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 47:410\u2013419. https:\/\/doi.org\/10.1183\/13993003.01359-2015","journal-title":"Eur Respir J"},{"key":"9204_CR10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1152\/physrev.00023.2019","volume":"100","author":"A Ray","year":"2020","unstructured":"Ray A, Camiolo M, Fitzpatrick A, Gauthier M, Wenzel SE (2020) Are We Meeting the Promise of Endotypes and Precision Medicine in Asthma? Physiol Rev 100:983\u20131017. https:\/\/doi.org\/10.1152\/physrev.00023.2019","journal-title":"Physiol Rev"},{"key":"9204_CR11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12931-025-03356-w","volume":"26","author":"C Xie","year":"2025","unstructured":"Xie C, Wang K, Yang K, Zhong Y, Gul A, Luo W et al (2025) Toward precision medicine in COPD: phenotypes, endotypes, biomarkers, and treatable traits. Respir Res 26:274. https:\/\/doi.org\/10.1186\/s12931-025-03356-w","journal-title":"Respir Res"},{"key":"9204_CR12","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1042\/CS20160487","volume":"131","author":"PJ Barnes","year":"2017","unstructured":"Barnes PJ (2017) Cellular and molecular mechanisms of asthma and COPD. Clin Sci (Lond) 131:1541\u20131558. https:\/\/doi.org\/10.1042\/CS20160487","journal-title":"Clin Sci (Lond)"},{"key":"9204_CR13","doi-asserted-by":"publisher","first-page":"1514846","DOI":"10.3389\/fmed.2025.1514846","volume":"12","author":"K Simmalee","year":"2025","unstructured":"Simmalee K, Kawamatawong T, Vitte J, Demoly P, Lumjiaktase P (2025) Exploring the pathogenesis and clinical implications of asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap (ACO): a narrative review. Front Med (Lausanne) 12:1514846. https:\/\/doi.org\/10.3389\/fmed.2025.1514846","journal-title":"Front Med (Lausanne)"},{"key":"9204_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1183\/20734735.026410","volume":"7","author":"PJ Barnes","year":"2011","unstructured":"Barnes PJ (2011) Similarities and differences in inflammatory mechanisms of asthma and COPD. Breathe 7:229\u2013238. https:\/\/doi.org\/10.1183\/20734735.026410","journal-title":"Breathe"},{"key":"9204_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.chest.2015.08.017","volume":"149","author":"PJ Barnes","year":"2016","unstructured":"Barnes PJ (2016) Asthma-COPD Overlap. Chest 149:7\u20138. https:\/\/doi.org\/10.1016\/j.chest.2015.08.017","journal-title":"Chest"},{"key":"9204_CR16","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","volume":"363","author":"JR Hurst","year":"2010","unstructured":"Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R et al (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363:1128\u20131138. https:\/\/doi.org\/10.1056\/NEJMoa0909883","journal-title":"N Engl J Med"},{"key":"9204_CR17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S0140-6736(17)30879-6","volume":"391","author":"ID Pavord","year":"2018","unstructured":"Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G et al (2018) After asthma: redefining airways diseases. Lancet 391:350\u2013400. https:\/\/doi.org\/10.1016\/S0140-6736(17)30879-6","journal-title":"Lancet"},{"key":"9204_CR18","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1001\/jama.2025.7358","volume":"333","author":"CODW Group","year":"2025","unstructured":"Group CODW, Can CI, Bhatt SP, Abadi E, Anzueto A, Bodduluri S et al (2025) A Multidimensional Diagnostic Approach for Chronic Obstructive Pulmonary Disease. JAMA 333:2164\u20132175. https:\/\/doi.org\/10.1001\/jama.2025.7358","journal-title":"JAMA"},{"key":"9204_CR19","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1111\/all.13760","volume":"74","author":"PJ Barnes","year":"2019","unstructured":"Barnes PJ (2019) Inflammatory endotypes in COPD. Allergy 74:1249\u20131256. https:\/\/doi.org\/10.1111\/all.13760","journal-title":"Allergy"},{"key":"9204_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jaip.2020.10.032","volume":"9","author":"P Lacwik","year":"2021","unstructured":"Lacwik P, Kupczyk M (2021) Asthma Phenotype Overlap: More May Be Less. J Allergy Clin Immunol Pract 9:363\u2013364. https:\/\/doi.org\/10.1016\/j.jaip.2020.10.032","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9204_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jaip.2020.07.048","volume":"9","author":"YY Han","year":"2021","unstructured":"Han YY, Zhang X, Wang J, Wang G, Oliver BG, Zhang HP et al (2021) Multidimensional Assessment of Asthma Identifies Clinically Relevant Phenotype Overlap: A Cross-Sectional Study. J Allergy Clin Immunol Pract 9:349\u201362e18. https:\/\/doi.org\/10.1016\/j.jaip.2020.07.048","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9204_CR22","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1016\/j.jaip.2024.06.010","volume":"12","author":"NG Papadopoulos","year":"2024","unstructured":"Papadopoulos NG, Bacharier LB, Jackson DJ, Deschildre A, Phipatanakul W, Szefler SJ et al (2024) Type 2 Inflammation and Asthma in Children: A Narrative Review. J Allergy Clin Immunol Pract 12:2310\u20132324. https:\/\/doi.org\/10.1016\/j.jaip.2024.06.010","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9204_CR23","doi-asserted-by":"publisher","first-page":"e70032","DOI":"10.1111\/pai.70032","volume":"36","author":"FR Skov","year":"2025","unstructured":"Skov FR, Sultan T, Fischer-Rasmussen K, Chawes BL, Stokholm J, Vahman N et al (2025) Type 2-high airway inflammation in childhood asthma distinguishes a more severe phenotype. Pediatr Allergy Immunol 36:e70032. https:\/\/doi.org\/10.1111\/pai.70032","journal-title":"Pediatr Allergy Immunol"},{"key":"9204_CR24","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.3390\/jcm14207137","volume":"14","author":"I Iwaszko","year":"2025","unstructured":"Iwaszko I, Specjalski K, Chelminska M, Niedoszytko M (2025) Neutrophilic Asthma-From Mechanisms to New Perspectives of Therapy. J Clin Med 14:7137. https:\/\/doi.org\/10.3390\/jcm14207137","journal-title":"J Clin Med"},{"key":"9204_CR25","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","volume":"50","author":"BN Lambrecht","year":"2019","unstructured":"Lambrecht BN, Hammad H, Fahy JV (2019) The Cytokines of Asthma. Immunity 50:975\u2013991. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.018","journal-title":"Immunity"},{"key":"9204_CR26","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S2213-2600(25)00174-2","volume":"13","author":"M Lommatzsch","year":"2025","unstructured":"Lommatzsch M, Buhl R, Bergmann KC, Brusselle GG, Canonica GW, Jackson DJ et al (2025) Eosinophils in asthma phenotypes: perpetrators or guilty by association? Lancet Respir Med 13:943\u2013950. https:\/\/doi.org\/10.1016\/S2213-2600(25)00174-2","journal-title":"Lancet Respir Med"},{"key":"9204_CR27","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41590-025-02212-9","volume":"26","author":"BN Lambrecht","year":"2025","unstructured":"Lambrecht BN, Ahmed E, Hammad H (2025) The immunology of asthma. Nat Immunol 26:1233\u20131245. https:\/\/doi.org\/10.1038\/s41590-025-02212-9","journal-title":"Nat Immunol"},{"key":"9204_CR28","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","volume":"184","author":"H Hammad","year":"2021","unstructured":"Hammad H, Lambrecht BN (2021) The basic immunology of asthma. Cell 184:1469\u20131485. https:\/\/doi.org\/10.1016\/j.cell.2021.02.016","journal-title":"Cell"},{"key":"9204_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/ni.3049","volume":"16","author":"BN Lambrecht","year":"2015","unstructured":"Lambrecht BN, Hammad H (2015) The immunology of asthma. Nat Immunol 16:45\u201356. https:\/\/doi.org\/10.1038\/ni.3049","journal-title":"Nat Immunol"},{"key":"9204_CR30","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1111\/all.16680","volume":"80","author":"D Lisik","year":"2025","unstructured":"Lisik D, Backman H, Basna R, Hedman L, Bashir MBA, Ercan S et al (2025) Late-Onset Asthma Phenotypes by Onset Age: A Cluster Analysis in Swedish Population-Based Cohorts. Allergy 80:3447\u20133451. https:\/\/doi.org\/10.1111\/all.16680","journal-title":"Allergy"},{"key":"9204_CR31","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1056\/NEJMra1712125","volume":"379","author":"AA White","year":"2018","unstructured":"White AA, Stevenson DD (2018) Aspirin-Exacerbated Respiratory Disease. N Engl J Med 379:1060\u20131070. https:\/\/doi.org\/10.1056\/NEJMra1712125","journal-title":"N Engl J Med"},{"key":"9204_CR32","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/all.15609","volume":"78","author":"GM Gauvreau","year":"2023","unstructured":"Gauvreau GM, Bergeron C, Boulet LP, Cockcroft DW, Cote A, Davis BE et al (2023) Sounding the alarmins-The role of alarmin cytokines in asthma. Allergy 78:402\u2013417. https:\/\/doi.org\/10.1111\/all.15609","journal-title":"Allergy"},{"key":"9204_CR33","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1111\/all.14526","volume":"75","author":"H Hong","year":"2020","unstructured":"Hong H, Liao S, Chen F, Yang Q, Wang DY (2020) Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type 2 inflammation. Allergy 75:2794\u20132804. https:\/\/doi.org\/10.1111\/all.14526","journal-title":"Allergy"},{"key":"9204_CR34","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A et al (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371:1198\u20131207. https:\/\/doi.org\/10.1056\/NEJMoa1403290","journal-title":"N Engl J Med"},{"key":"9204_CR35","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","volume":"384","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME et al (2021) Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med 384:1800\u20131809. https:\/\/doi.org\/10.1056\/NEJMoa2034975","journal-title":"N Engl J Med"},{"key":"9204_CR36","doi-asserted-by":"publisher","first-page":"2300826","DOI":"10.1183\/13993003.00826-2023","volume":"64","author":"T Liu","year":"2024","unstructured":"Liu T, Woodruff PG, Zhou X (2024) Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies. Eur Respir J 64:2300826. https:\/\/doi.org\/10.1183\/13993003.00826-2023","journal-title":"Eur Respir J"},{"key":"9204_CR37","doi-asserted-by":"publisher","first-page":"2102669","DOI":"10.1183\/13993003.02669-2021","volume":"59","author":"SF Seys","year":"2022","unstructured":"Seys SF, Long MB (2022) The quest for biomarkers in asthma: challenging the T2 versus non-T2 paradigm. Eur Respir J 59:2102669. https:\/\/doi.org\/10.1183\/13993003.02669-2021","journal-title":"Eur Respir J"},{"key":"9204_CR38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/MCP.0000000000000543","volume":"25","author":"SF Seys","year":"2019","unstructured":"Seys SF, Lokwani R, Simpson JL, Bullens DMA (2019) New insights in neutrophilic asthma. Curr Opin Pulm Med 25:113\u2013120. https:\/\/doi.org\/10.1097\/MCP.0000000000000543","journal-title":"Curr Opin Pulm Med"},{"key":"9204_CR39","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.it.2017.07.003","volume":"38","author":"A Ray","year":"2017","unstructured":"Ray A, Kolls JK (2017) Neutrophilic Inflammation in Asthma and Association with Disease Severity. Trends Immunol 38:942\u2013954. https:\/\/doi.org\/10.1016\/j.it.2017.07.003","journal-title":"Trends Immunol"},{"key":"9204_CR40","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaci.2016.10.034","volume":"140","author":"FLM Ricciardolo","year":"2017","unstructured":"Ricciardolo FLM, Sorbello V, Folino A, Gallo F, Massaglia GM, Favata G et al (2017) Identification of IL-17F\/frequent exacerbator endotype in asthma. J Allergy Clin Immunol 140:395\u2013406. https:\/\/doi.org\/10.1016\/j.jaci.2016.10.034","journal-title":"J Allergy Clin Immunol"},{"key":"9204_CR41","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.coi.2013.08.002","volume":"25","author":"DC Newcomb","year":"2013","unstructured":"Newcomb DC, Peebles RS Jr (2013) Th17-mediated inflammation in asthma. Curr Opin Immunol 25:755\u2013760. https:\/\/doi.org\/10.1016\/j.coi.2013.08.002","journal-title":"Curr Opin Immunol"},{"key":"9204_CR42","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2147\/COPD.S136592","volume":"12","author":"MA Ponce-Gallegos","year":"2017","unstructured":"Ponce-Gallegos MA, Ramirez-Venegas A, Falfan-Valencia R (2017) Th17 profile in COPD exacerbations. Int J Chron Obstruct Pulmon Dis 12:1857\u20131865. https:\/\/doi.org\/10.2147\/COPD.S136592","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"9204_CR43","doi-asserted-by":"publisher","first-page":"e20695","DOI":"10.1002\/advs.202520695","volume":"13","author":"H Liu","year":"2026","unstructured":"Liu H, Aili A, Kuang Z, Cao L, Li Z, Shang Y et al (2026) Endogenous Ceramide 24:1 Constrains Th17-Driven Neutrophilic Inflammation by Antagonizing EP2 Signaling. Adv Sci (Weinh) 13:e20695. https:\/\/doi.org\/10.1002\/advs.202520695","journal-title":"Adv Sci (Weinh)"},{"key":"9204_CR44","doi-asserted-by":"publisher","unstructured":"Plavsic A, Bonaci-Nikolic B, Milenkovic B, Miskovic R, Kusic N, Dimitrijevic M et al (2024) Asthma Inflammatory Phenotypes: How Can We Distinguish Them? J Clin Med 13:526. https:\/\/doi.org\/10.3390\/jcm13020526","DOI":"10.3390\/jcm13020526"},{"key":"9204_CR45","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S2213-2600(16)30227-2","volume":"4","author":"PM O\u2019Byrne","year":"2016","unstructured":"O\u2019Byrne PM, Metev H, Puu M, Richter K, Keen C, Uddin M et al (2016) Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 4:797\u2013806. https:\/\/doi.org\/10.1016\/S2213-2600(16)30227-2","journal-title":"Lancet Respir Med"},{"key":"9204_CR46","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00528-2020","author":"TSC Hinks","year":"2021","unstructured":"Hinks TSC, Levine SJ, Brusselle GG (2021) Treatment options in type-2 low asthma. Eur Respir J 57. https:\/\/doi.org\/10.1183\/13993003.00528-2020","journal-title":"Eur Respir J 57"},{"key":"9204_CR47","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jaci.2018.06.008","volume":"143","author":"O Tliba","year":"2019","unstructured":"Tliba O, Panettieri RA Jr (2019) Paucigranulocytic asthma: Uncoupling of airway obstruction from inflammation. J Allergy Clin Immunol 143:1287\u20131294. https:\/\/doi.org\/10.1016\/j.jaci.2018.06.008","journal-title":"J Allergy Clin Immunol"},{"key":"9204_CR48","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/thx.2009.126722","volume":"65","author":"DC Cowan","year":"2010","unstructured":"Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR (2010) Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 65:384\u2013390. https:\/\/doi.org\/10.1136\/thx.2009.126722","journal-title":"Thorax"},{"key":"9204_CR49","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.3390\/biomedicines11102797","volume":"11","author":"H Shailesh","year":"2023","unstructured":"Shailesh H, Bhat AA, Janahi IA (2023) Obesity-Associated Non-T2 Mechanisms in Obese Asthmatic Individuals. Biomedicines 11:2797. https:\/\/doi.org\/10.3390\/biomedicines11102797","journal-title":"Biomedicines"},{"key":"9204_CR50","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/s12931-024-03077-6","volume":"25","author":"H Tang","year":"2024","unstructured":"Tang H, Li Z, Yang C, Fu L, Ji X, Chen Z et al (2024) CTSS contributes to airway neutrophilic inflammation in mixed granulocytic asthma. Respir Res 25:441. https:\/\/doi.org\/10.1186\/s12931-024-03077-6","journal-title":"Respir Res"},{"key":"9204_CR51","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1164\/rccm.202009-3713OC","volume":"203","author":"AT Hastie","year":"2021","unstructured":"Hastie AT, Mauger DT, Denlinger LC, Coverstone A, Castro M, Erzurum S et al (2021) Mixed Sputum Granulocyte Longitudinal Impact on Lung Function in the Severe Asthma Research Program. Am J Respir Crit Care Med 203:882\u2013892. https:\/\/doi.org\/10.1164\/rccm.202009-3713OC","journal-title":"Am J Respir Crit Care Med"},{"key":"9204_CR52","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.jaci.2014.05.038","volume":"134","author":"C Irvin","year":"2014","unstructured":"Irvin C, Zafar I, Good J, Rollins D, Christianson C, Gorska MM et al (2014) Increased frequency of dual-positive TH2\/TH17 cells in bronchoalveolar lavage fluid characterizes a population of patients with severe asthma. J Allergy Clin Immunol 134:1175\u201386e7. https:\/\/doi.org\/10.1016\/j.jaci.2014.05.038","journal-title":"J Allergy Clin Immunol"},{"key":"9204_CR53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jacig.2022.08.003","volume":"2","author":"TFC Fraga-Silva","year":"2023","unstructured":"Fraga-Silva TFC, Boko MMM, Martins NS, Cetlin AA, Russo M, Vianna EO et al (2023) Asthma-associated bacterial infections: Are they protective or deleterious? J Allergy Clin Immunol Glob 2:14\u201322. https:\/\/doi.org\/10.1016\/j.jacig.2022.08.003","journal-title":"J Allergy Clin Immunol Glob"},{"key":"9204_CR54","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1710-1492-3-2-60","volume":"3","author":"S Siddiqui","year":"2007","unstructured":"Siddiqui S, Brightling CE (2007) Airways disease: phenotyping heterogeneity using measures of airway inflammation. Allergy Asthma Clin Immunol 3:60\u201369. https:\/\/doi.org\/10.1186\/1710-1492-3-2-60","journal-title":"Allergy Asthma Clin Immunol"},{"key":"9204_CR55","doi-asserted-by":"publisher","first-page":"175346662513358","DOI":"10.1177\/17534666251335800","volume":"19","author":"M Vanetti","year":"2025","unstructured":"Vanetti M, Visca D, Ardesi F, Zappa M, Pignatti P, Spanevello A (2025) Eosinophils in chronic obstructive pulmonary disease. Ther Adv Respir Dis 19:17534666251335800. https:\/\/doi.org\/10.1177\/17534666251335800","journal-title":"Ther Adv Respir Dis"},{"key":"9204_CR56","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1042\/CS20255452","volume":"139","author":"M Fricker","year":"2025","unstructured":"Fricker M, Lokwani R (2025) COPD: the role of neutrophils in inflammation, pathophysiology, and as drug targets. Clin Sci (Lond) 139:1199\u20131214. https:\/\/doi.org\/10.1042\/CS20255452","journal-title":"Clin Sci (Lond)"},{"key":"9204_CR57","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2147\/COPD.S506616","volume":"20","author":"DEM Razia","year":"2025","unstructured":"Razia DEM, Gao C, Wang C, An Y, Wang F, Liu L et al (2025) Targeting Non-Eosinophilic Immunological Pathways in COPD and AECOPD: Current Insights and Therapeutic Strategies. Int J Chron Obstruct Pulmon Dis 20:511\u2013532. https:\/\/doi.org\/10.2147\/COPD.S506616","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"9204_CR58","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.3390\/ijms26073365","volume":"26","author":"CC Lan","year":"2025","unstructured":"Lan CC, Yang MC, Su WL, Huang KL, Lin CC, Huang YC et al (2025) Unraveling the Immune Landscape of Chronic Obstructive Pulmonary Disease: Insights into Inflammatory Cell Subtypes, Pathogenesis, and Treatment Strategies. Int J Mol Sci 26:3365. https:\/\/doi.org\/10.3390\/ijms26073365","journal-title":"Int J Mol Sci"},{"key":"9204_CR59","doi-asserted-by":"publisher","first-page":"1651808","DOI":"10.3389\/fimmu.2025.1651808","volume":"16","author":"H Li","year":"2025","unstructured":"Li H, Wang Y, Duan H, Bao Y, Deng X, He Y et al (2025) Immune cell regulatory networks in chronic obstructive pulmonary disease: mechanistic analysis from innate to adaptive immunity. Front Immunol 16:1651808. https:\/\/doi.org\/10.3389\/fimmu.2025.1651808","journal-title":"Front Immunol"},{"key":"9204_CR60","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12931-022-02153-z","volume":"23","author":"X Su","year":"2022","unstructured":"Su X, Wu W, Zhu Z, Lin X, Zeng Y (2022) The effects of epithelial-mesenchymal transitions in COPD induced by cigarette smoke: an update. Respir Res 23:225. https:\/\/doi.org\/10.1186\/s12931-022-02153-z","journal-title":"Respir Res"},{"key":"9204_CR61","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1183\/09031936.00018908","volume":"31","author":"KF Chung","year":"2008","unstructured":"Chung KF, Adcock IM (2008) Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 31:1334\u20131356. https:\/\/doi.org\/10.1183\/09031936.00018908","journal-title":"Eur Respir J"},{"key":"9204_CR62","doi-asserted-by":"publisher","first-page":"e70046","DOI":"10.1111\/bcpt.70046","volume":"136","author":"M Brollo","year":"2025","unstructured":"Brollo M, Marquant Q, Salvator H, Cohen J, Glorion M, Ferre A et al (2025) Differences in the Inflammatory Response and Corticoid Responsiveness of Human Lung Macrophages and Parenchymal Explants Exposed to Cigarette Smoke Extracts. Basic Clin Pharmacol Toxicol 136:e70046. https:\/\/doi.org\/10.1111\/bcpt.70046","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"9204_CR63","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1164\/rccm.2107139","volume":"165","author":"M Saetta","year":"2002","unstructured":"Saetta M, Mariani M, Panina-Bordignon P, Turato G, Buonsanti C, Baraldo S et al (2002) Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 165:1404\u20131409. https:\/\/doi.org\/10.1164\/rccm.2107139","journal-title":"Am J Respir Crit Care Med"},{"key":"9204_CR64","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1111\/bcp.12724","volume":"80","author":"S Jurcevic","year":"2015","unstructured":"Jurcevic S, Humfrey C, Uddin M, Warrington S, Larsson B, Keen C (2015) The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions. Br J Clin Pharmacol 80:1324\u20131336. https:\/\/doi.org\/10.1111\/bcp.12724","journal-title":"Br J Clin Pharmacol"},{"key":"9204_CR65","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1164\/ajrccm.160.supplement_1.17","volume":"160","author":"PJ Barnes","year":"1999","unstructured":"Barnes PJ (1999) Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:S72\u2013S79. https:\/\/doi.org\/10.1164\/ajrccm.160.supplement_1.17","journal-title":"Am J Respir Crit Care Med"},{"key":"9204_CR66","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1165\/rcmb.2012-0492TR","volume":"48","author":"K Hoenderdos","year":"2013","unstructured":"Hoenderdos K, Condliffe A (2013) The neutrophil in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 48:531\u2013539. https:\/\/doi.org\/10.1165\/rcmb.2012-0492TR","journal-title":"Am J Respir Cell Mol Biol"},{"key":"9204_CR67","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/2049-6958-6-4-210","volume":"6","author":"G Invernizzi","year":"2011","unstructured":"Invernizzi G (2011) Persistence of systemic inflammation in COPD in spite of smoking cessation. Multidiscip Respir Med 6:210\u2013211. https:\/\/doi.org\/10.1186\/2049-6958-6-4-210","journal-title":"Multidiscip Respir Med"},{"key":"9204_CR68","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/15412555.2017.1335697","volume":"14","author":"A Eich","year":"2017","unstructured":"Eich A, Urban V, Jutel M, Vlcek J, Shim JJ, Trofimov VI et al (2017) A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease. COPD 14:476\u2013483. https:\/\/doi.org\/10.1080\/15412555.2017.1335697","journal-title":"COPD"},{"key":"9204_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15326\/jcopdf.7.1.2019.0138","volume":"7","author":"CP Hersh","year":"2020","unstructured":"Hersh CP, Zacharia S, Prakash Arivu Chelvan R, Hayden LP, Mirtar A, Zarei S et al (2020) Immunoglobulin E as a Biomarker for the Overlap of Atopic Asthma and Chronic Obstructive Pulmonary Disease. Chronic Obstr Pulm Dis 7:1\u201312. https:\/\/doi.org\/10.15326\/jcopdf.7.1.2019.0138","journal-title":"Chronic Obstr Pulm Dis"},{"key":"9204_CR70","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2303951","volume":"389","author":"SP Bhatt","year":"2023","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M et al (2023) Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med 389:205\u2013214. https:\/\/doi.org\/10.1056\/NEJMoa2303951","journal-title":"N Engl J Med"},{"key":"9204_CR71","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1164\/rccm.200701-014OC","volume":"177","author":"CA Feghali-Bostwick","year":"2008","unstructured":"Feghali-Bostwick CA, Gadgil AS, Otterbein LE, Pilewski JM, Stoner MW, Csizmadia E et al (2008) Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177:156\u2013163. https:\/\/doi.org\/10.1164\/rccm.200701-014OC","journal-title":"Am J Respir Crit Care Med"},{"key":"9204_CR72","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jaci.2012.06.025","volume":"130","author":"G Jia","year":"2012","unstructured":"Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD et al (2012) Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 130:647\u201354e10. https:\/\/doi.org\/10.1016\/j.jaci.2012.06.025","journal-title":"J Allergy Clin Immunol"},{"key":"9204_CR73","doi-asserted-by":"publisher","first-page":"1700800","DOI":"10.1183\/13993003.00800-2017","volume":"50","author":"JL Gomez","year":"2017","unstructured":"Gomez JL, Yan X, Holm CT, Grant N, Liu Q, Cohn L et al (2017) Characterisation of asthma subgroups associated with circulating YKL-40 levels. Eur Respir J 50:1700800. https:\/\/doi.org\/10.1183\/13993003.00800-2017","journal-title":"Eur Respir J"},{"key":"9204_CR74","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jaci.2019.08.031","volume":"145","author":"X Li","year":"2020","unstructured":"Li X, Hastie AT, Peters MC, Hawkins GA, Phipatanakul W, Li H et al (2020) Investigation of the relationship between IL-6 and type 2 biomarkers in patients with severe asthma. J Allergy Clin Immunol 145:430\u2013433. https:\/\/doi.org\/10.1016\/j.jaci.2019.08.031","journal-title":"J Allergy Clin Immunol"},{"key":"9204_CR75","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1067\/mai.2001.117880","volume":"108","author":"W Busse","year":"2001","unstructured":"Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD et al (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108:184\u2013190. https:\/\/doi.org\/10.1067\/mai.2001.117880","journal-title":"J Allergy Clin Immunol"},{"key":"9204_CR76","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nm.2755","volume":"18","author":"SJ Galli","year":"2012","unstructured":"Galli SJ, Tsai M (2012) IgE and mast cells in allergic disease. Nat Med 18:693\u2013704. https:\/\/doi.org\/10.1038\/nm.2755","journal-title":"Nat Med"},{"key":"9204_CR77","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.anai.2015.10.027","volume":"116","author":"TN Tran","year":"2016","unstructured":"Tran TN, Zeiger RS, Peters SP, Colice G, Newbold P, Goldman M et al (2016) Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol 116:37\u201342. https:\/\/doi.org\/10.1016\/j.anai.2015.10.027","journal-title":"Ann Allergy Asthma Immunol"},{"key":"9204_CR78","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1183\/09031936.01.00092101","volume":"18","author":"M Soler","year":"2001","unstructured":"Soler M, Matz J, Townley R, Buhl R, O\u2019Brien J, Fox H et al (2001) The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18:254\u2013261. https:\/\/doi.org\/10.1183\/09031936.01.00092101","journal-title":"Eur Respir J"},{"key":"9204_CR79","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s40265-023-01905-5","volume":"83","author":"C Domingo","year":"2023","unstructured":"Domingo C, Mirapeix RM, Gonzalez-Barcala FJ, Forne C, Garcia F (2023) Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study. Drugs 83:1111\u20131123. https:\/\/doi.org\/10.1007\/s40265-023-01905-5","journal-title":"Drugs"},{"key":"9204_CR80","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON et al (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380:651\u2013659. https:\/\/doi.org\/10.1016\/S0140-6736(12)60988-X","journal-title":"Lancet"},{"key":"9204_CR81","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P et al (2016) Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388:2115\u20132127. https:\/\/doi.org\/10.1016\/S0140-6736(16)31324-1","journal-title":"Lancet"},{"key":"9204_CR82","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M et al (2016) Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388:2128\u20132141. https:\/\/doi.org\/10.1016\/S0140-6736(16)31322-8","journal-title":"Lancet"},{"key":"9204_CR83","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","volume":"391","author":"DJ Jackson","year":"2024","unstructured":"Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE et al (2024) Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. N Engl J Med 391:2337\u20132349. https:\/\/doi.org\/10.1056\/NEJMoa2406673","journal-title":"N Engl J Med"},{"key":"9204_CR84","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF et al (2018) Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med 378:2486\u20132496. https:\/\/doi.org\/10.1056\/NEJMoa1804092","journal-title":"N Engl J Med"},{"key":"9204_CR85","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A et al (2022) Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med 10:11\u201325. https:\/\/doi.org\/10.1016\/S2213-2600(21)00322-2","journal-title":"Lancet Respir Med"},{"key":"9204_CR86","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jaip.2022.11.044","volume":"11","author":"G Brusselle","year":"2023","unstructured":"Brusselle G, Quirce S, Papi A, Kuna P, Chipps BE, Hanania NA et al (2023) Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma. J Allergy Clin Immunol Pract 11:873\u201384e11. https:\/\/doi.org\/10.1016\/j.jaip.2022.11.044","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9204_CR87","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.jaip.2022.11.043","volume":"11","author":"ID Pavord","year":"2023","unstructured":"Pavord ID, Deniz Y, Corren J, Casale TB, FitzGerald JM, Izuhara K et al (2023) Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma. J Allergy Clin Immunol Pract 11:1213\u201320e2. https:\/\/doi.org\/10.1016\/j.jaip.2022.11.043","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9204_CR88","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.alit.2024.02.002","volume":"73","author":"T Tajiri","year":"2024","unstructured":"Tajiri T, Suzuki M, Nishiyama H, Ozawa Y, Kurokawa R, Takeda N et al (2024) Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: A prospective, observational study. Allergol Int 73:406\u2013415. https:\/\/doi.org\/10.1016\/j.alit.2024.02.002","journal-title":"Allergol Int"},{"key":"9204_CR89","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc\u2019h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S et al (2020) Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation. Allergy 75:1188\u20131204. https:\/\/doi.org\/10.1111\/all.14151","journal-title":"Allergy"},{"key":"9204_CR90","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S2213-2600(24)00409-0","volume":"13","author":"SP Bhatt","year":"2025","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA et al (2025) Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 13:234\u2013243. https:\/\/doi.org\/10.1016\/S2213-2600(24)00409-0","journal-title":"Lancet Respir Med"},{"key":"9204_CR91","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2147\/JAA.S342391","volume":"17","author":"R Panettieri Jr","year":"2024","unstructured":"Panettieri R Jr., Lugogo N, Corren J, Ambrose CS (2024) Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types. J Asthma Allergy 17:219\u2013236. https:\/\/doi.org\/10.2147\/JAA.S342391","journal-title":"J Asthma Allergy"},{"key":"9204_CR92","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12931-020-01526-6","volume":"21","author":"A Menzies-Gow","year":"2020","unstructured":"Menzies-Gow A, Colice G, Griffiths JM, Almqvist G, Ponnarambil S, Kaur P et al (2020) NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res 21:266. https:\/\/doi.org\/10.1186\/s12931-020-01526-6","journal-title":"Respir Res"},{"key":"9204_CR93","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","volume":"208","author":"J Corren","year":"2023","unstructured":"Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B et al (2023) Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials. Am J Respir Crit Care Med 208:13\u201324. https:\/\/doi.org\/10.1164\/rccm.202210-2005OC","journal-title":"Am J Respir Crit Care Med"},{"key":"9204_CR94","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","volume":"13","author":"D Singh","year":"2025","unstructured":"Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB et al (2025) Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial. Lancet Respir Med 13:47\u201358. https:\/\/doi.org\/10.1016\/S2213-2600(24)00324-2","journal-title":"Lancet Respir Med"},{"key":"9204_CR95","doi-asserted-by":"publisher","first-page":"240088","DOI":"10.1183\/16000617.0088-2024","volume":"34","author":"B Gyawali","year":"2025","unstructured":"Gyawali B, Georas SN, Khurana S (2025) Biologics in severe asthma: a state-of-the-art review. Eur Respir Rev 34:240088. https:\/\/doi.org\/10.1183\/16000617.0088-2024","journal-title":"Eur Respir Rev"},{"key":"9204_CR96","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1111\/cea.13731","volume":"50","author":"CD Austin","year":"2020","unstructured":"Austin CD, Gonzalez Edick M, Ferrando RE, Solon M, Baca M, Mesh K et al (2020) A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER). Clin Exp Allergy 50:1342\u20131351. https:\/\/doi.org\/10.1111\/cea.13731","journal-title":"Clin Exp Allergy"},{"key":"9204_CR97","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","volume":"6","author":"RA Panettieri Jr","year":"2018","unstructured":"Panettieri RA Jr., Sjobring U, Peterffy A, Wessman P, Bowen K, Piper E et al (2018) Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med 6:511\u2013525. https:\/\/doi.org\/10.1016\/S2213-2600(18)30184-X","journal-title":"Lancet Respir Med"},{"key":"9204_CR98","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S2213-2600(20)30412-4","volume":"9","author":"CE Brightling","year":"2021","unstructured":"Brightling CE, Gaga M, Inoue H, Li J, Maspero J, Wenzel S et al (2021) Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials. Lancet Respir Med 9:43\u201356. https:\/\/doi.org\/10.1016\/S2213-2600(20)30412-4","journal-title":"Lancet Respir Med"},{"key":"9204_CR99","doi-asserted-by":"publisher","first-page":"100847","DOI":"10.1016\/j.eclinm.2021.100847","volume":"35","author":"M Castro","year":"2021","unstructured":"Castro M, Kerwin E, Miller D, Pedinoff A, Sher L, Cardenas P et al (2021) Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2). EClinicalMedicine 35:100847. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100847","journal-title":"EClinicalMedicine"},{"key":"9204_CR100","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3904\/kjim.2023.299","volume":"39","author":"QL Quoc","year":"2024","unstructured":"Quoc QL, Choi Y, Hur GY, Park HS (2024) New targets for type 2-low asthma. Korean J Intern Med 39:215\u2013227. https:\/\/doi.org\/10.3904\/kjim.2023.299","journal-title":"Korean J Intern Med"},{"key":"9204_CR101","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","volume":"188","author":"WW Busse","year":"2013","unstructured":"Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J et al (2013) Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 188:1294\u20131302. https:\/\/doi.org\/10.1164\/rccm.201212-2318OC","journal-title":"Am J Respir Crit Care Med"},{"key":"9204_CR102","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1056\/NEJMoa2030880","volume":"385","author":"CE Brightling","year":"2021","unstructured":"Brightling CE, Nair P, Cousins DJ, Louis R, Singh D (2021) Risankizumab in Severe Asthma - A Phase 2a, Placebo-Controlled Trial. N Engl J Med 385:1669\u20131679. https:\/\/doi.org\/10.1056\/NEJMoa2030880","journal-title":"N Engl J Med"},{"key":"9204_CR103","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1183\/09031936.00063510","volume":"37","author":"ST Holgate","year":"2011","unstructured":"Holgate ST, Noonan M, Chanez P, Busse W, Dupont L, Pavord I et al (2011) Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J 37:1352\u20131359. https:\/\/doi.org\/10.1183\/09031936.00063510","journal-title":"Eur Respir J"},{"key":"9204_CR104","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1136\/thoraxjnl-2012-202698","volume":"68","author":"GG Brusselle","year":"2013","unstructured":"Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V et al (2013) Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 68:322\u2013329. https:\/\/doi.org\/10.1136\/thoraxjnl-2012-202698","journal-title":"Thorax"},{"key":"9204_CR105","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","volume":"390","author":"PG Gibson","year":"2017","unstructured":"Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL et al (2017) Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet 390:659\u2013668. https:\/\/doi.org\/10.1016\/S0140-6736(17)31281-3","journal-title":"Lancet"},{"key":"9204_CR106","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1136\/thoraxjnl-2020-216331","volume":"76","author":"SD Shukla","year":"2021","unstructured":"Shukla SD, Taylor SL, Gibson PG, Barker D, Upham JW, Yang IA et al (2021) Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy. Thorax 76:733\u2013736. https:\/\/doi.org\/10.1136\/thoraxjnl-2020-216331","journal-title":"Thorax"},{"key":"9204_CR107","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1183\/20734735.025118","volume":"14","author":"L Lahousse","year":"2018","unstructured":"Lahousse L (2018) Amazing pleiotropic effects of azithromycin. Breathe (Sheff) 14:336\u2013337. https:\/\/doi.org\/10.1183\/20734735.025118","journal-title":"Breathe (Sheff)"},{"key":"9204_CR108","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1164\/rccm.200903-0354OC","volume":"181","author":"M Castro","year":"2010","unstructured":"Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL et al (2010) Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 181:116\u2013124. https:\/\/doi.org\/10.1164\/rccm.200903-0354OC","journal-title":"Am J Respir Crit Care Med"},{"key":"9204_CR109","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S2213-2600(20)30408-2","volume":"9","author":"R Chaudhuri","year":"2021","unstructured":"Chaudhuri R, Rubin A, Sumino K, Lapa ESJR, Niven R, Siddiqui S et al (2021) Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials. Lancet Respir Med 9:457\u2013466. https:\/\/doi.org\/10.1016\/S2213-2600(20)30408-2","journal-title":"Lancet Respir Med"},{"key":"9204_CR110","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","volume":"71","author":"ID Pavord","year":"2016","unstructured":"Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA et al (2016) Blood eosinophils and inhaled corticosteroid\/long-acting beta-2 agonist efficacy in COPD. Thorax 71:118\u2013125. https:\/\/doi.org\/10.1136\/thoraxjnl-2015-207021","journal-title":"Thorax"},{"key":"9204_CR111","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S2213-2600(16)30148-5","volume":"4","author":"ID Pavord","year":"2016","unstructured":"Pavord ID, Lettis S, Anzueto A, Barnes N (2016) Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med 4:731\u2013741. https:\/\/doi.org\/10.1016\/S2213-2600(16)30148-5","journal-title":"Lancet Respir Med"},{"key":"9204_CR112","doi-asserted-by":"publisher","first-page":"230229","DOI":"10.1183\/20734735.0229-2023","volume":"20","author":"A Beech","year":"2024","unstructured":"Beech A, Higham A, Booth S, Tejwani V, Trinkmann F, Singh D (2024) Type 2 inflammation in COPD: is it just asthma? Breathe (Sheff) 20:230229. https:\/\/doi.org\/10.1183\/20734735.0229-2023","journal-title":"Breathe (Sheff)"},{"key":"9204_CR113","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4046\/trd.2020.0026","volume":"83","author":"D Singh","year":"2020","unstructured":"Singh D (2020) Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: A Biomarker of Inhaled Corticosteroid Effects. Tuberc Respir Dis (Seoul) 83:185\u2013194. https:\/\/doi.org\/10.4046\/trd.2020.0026","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"9204_CR114","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","volume":"390","author":"SP Bhatt","year":"2024","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA et al (2024) Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med 390:2274\u20132283. https:\/\/doi.org\/10.1056\/NEJMoa2401304","journal-title":"N Engl J Med"},{"key":"9204_CR115","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","volume":"377","author":"ID Pavord","year":"2017","unstructured":"Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N et al (2017) Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. N Engl J Med 377:1613\u20131629. https:\/\/doi.org\/10.1056\/NEJMoa1708208","journal-title":"N Engl J Med"},{"key":"9204_CR116","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2147\/COPD.S294333","volume":"16","author":"ID Pavord","year":"2021","unstructured":"Pavord ID, Chapman KR, Bafadhel M, Sciurba FC, Bradford ES, Schweiker Harris S et al (2021) Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO. Int J Chron Obstruct Pulmon Dis 16:1755\u20131770. https:\/\/doi.org\/10.2147\/COPD.S294333","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"9204_CR117","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","volume":"392","author":"FC Sciurba","year":"2025","unstructured":"Sciurba FC, Criner GJ, Christenson SA, Martinez FJ, Papi A, Roche N et al (2025) Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype. N Engl J Med 392:1710\u20131720. https:\/\/doi.org\/10.1056\/NEJMoa2413181","journal-title":"N Engl J Med"},{"key":"9204_CR118","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","volume":"381","author":"GJ Criner","year":"2019","unstructured":"Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D et al (2019) Benralizumab for the Prevention of COPD Exacerbations. N Engl J Med 381:1023\u20131034. https:\/\/doi.org\/10.1056\/NEJMoa1905248","journal-title":"N Engl J Med"},{"key":"9204_CR119","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S2213-2600(19)30338-8","volume":"8","author":"GJ Criner","year":"2020","unstructured":"Criner GJ, Celli BR, Singh D, Agusti A, Papi A, Jison M et al (2020) Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respir Med 8:158\u2013170. https:\/\/doi.org\/10.1016\/S2213-2600(19)30338-8","journal-title":"Lancet Respir Med"},{"key":"9204_CR120","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00563-2019","author":"ET Osei","year":"2020","unstructured":"Osei ET, Brandsma CA, Timens W, Heijink IH, Hackett TL (2020) Current perspectives on the role of interleukin-1 signalling in the pathogenesis of asthma and COPD. Eur Respir J 55. https:\/\/doi.org\/10.1183\/13993003.00563-2019","journal-title":"Eur Respir J 55"},{"key":"9204_CR121","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12931-017-0633-7","volume":"18","author":"PMA Calverley","year":"2017","unstructured":"Calverley PMA, Sethi S, Dawson M, Ward CK, Finch DK, Penney M et al (2017) A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease. Respir Res 18:153. https:\/\/doi.org\/10.1186\/s12931-017-0633-7","journal-title":"Respir Res"},{"key":"9204_CR122","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1164\/rccm.200501-147OC","volume":"172","author":"H van der Vaart","year":"2005","unstructured":"van der Vaart H, Koeter GH, Postma DS, Kauffman HF, ten Hacken NH (2005) First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172:465\u2013469. https:\/\/doi.org\/10.1164\/rccm.200501-147OC","journal-title":"Am J Respir Crit Care Med"},{"key":"9204_CR123","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.rmed.2012.11.008","volume":"107","author":"SI Rennard","year":"2013","unstructured":"Rennard SI, Flavin SK, Agarwal PK, Lo KH, Barnathan ES (2013) Long-term safety study of infliximab in moderate-to-severe chronic obstructive pulmonary disease. Respir Med 107:424\u2013432. https:\/\/doi.org\/10.1016\/j.rmed.2012.11.008","journal-title":"Respir Med"},{"key":"9204_CR124","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.2147\/COPD.S419056","volume":"18","author":"M Cazzola","year":"2023","unstructured":"Cazzola M, Hanania NA, Page CP, Matera MG (2023) Novel Anti-Inflammatory Approaches to COPD. Int J Chron Obstruct Pulmon Dis 18:1333\u20131352. https:\/\/doi.org\/10.2147\/COPD.S419056","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"9204_CR125","doi-asserted-by":"publisher","first-page":"1346491","DOI":"10.3389\/fimmu.2024.1346491","volume":"15","author":"RK Kortekaas","year":"2024","unstructured":"Kortekaas RK, Geillinger-Kastle KE, Fuentes-Mateos R, van Orsoy R, Al-Alyan N, Burgess JK et al (2024) The disruptive effects of COPD exacerbation-associated factors on epithelial repair responses. Front Immunol 15:1346491. https:\/\/doi.org\/10.3389\/fimmu.2024.1346491","journal-title":"Front Immunol"},{"key":"9204_CR126","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2606998","author":"FC Sciurba","year":"2026","unstructured":"Sciurba FC, Watz H, Bourdin A, Janssens W, Martinez FJ, Zheng J et al (2026) Tozorakimab to Prevent COPD Exacerbations. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2606998","journal-title":"N Engl J Med"},{"key":"9204_CR127","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(26)00637-9","volume":"407","author":"A Papi","year":"2026","unstructured":"Papi A, Greening NJ, Bhatt SP, Roche N, Celli B, Wedzicha JA et al (2026) Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials. Lancet 407:2027\u20132039. https:\/\/doi.org\/10.1016\/S0140-6736(26)00637-9","journal-title":"Lancet"},{"key":"9204_CR128","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0140-6736(14)62410-7","volume":"385","author":"FJ Martinez","year":"2015","unstructured":"Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF (2015) Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 385:857\u2013866. https:\/\/doi.org\/10.1016\/S0140-6736(14)62410-7","journal-title":"Lancet"},{"key":"9204_CR129","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S2213-2600(18)30331-X","volume":"6","author":"KF Rabe","year":"2018","unstructured":"Rabe KF, Watz H, Baraldo S, Pedersen F, Biondini D, Bagul N et al (2018) Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial. Lancet Respir Med 6:827\u2013836. https:\/\/doi.org\/10.1016\/S2213-2600(18)30331-X","journal-title":"Lancet Respir Med"},{"key":"9204_CR130","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMoa1104623","volume":"365","author":"RK Albert","year":"2011","unstructured":"Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr., Criner GJ et al (2011) Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365:689\u2013698. https:\/\/doi.org\/10.1056\/NEJMoa1104623","journal-title":"N Engl J Med"},{"key":"9204_CR131","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1164\/ajrccm.162.5.9910112","volume":"162","author":"A Papi","year":"2000","unstructured":"Papi A, Romagnoli M, Baraldo S, Braccioni F, Guzzinati I, Saetta M et al (2000) Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 162:1773\u20131777. https:\/\/doi.org\/10.1164\/ajrccm.162.5.9910112","journal-title":"Am J Respir Crit Care Med"},{"key":"9204_CR132","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1183\/09031936.04.00116004","volume":"23","author":"DE O\u2019Donnell","year":"2004","unstructured":"O\u2019Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B et al (2004) Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23:832\u2013840. https:\/\/doi.org\/10.1183\/09031936.04.00116004","journal-title":"Eur Respir J"},{"key":"9204_CR133","doi-asserted-by":"publisher","first-page":"e003750","DOI":"10.1136\/bmjresp-2025-003750","volume":"12","author":"M Gronnier","year":"2025","unstructured":"Gronnier M, Desy L, Pouliot L, Lemieux SE, Vezina FA, Lachapelle P et al (2025) Integrating blood eosinophils and exhaled nitric oxide (FeNO) in asthma diagnostic pathways for adults and children: the PROPULSION SANTE observational study with translational sub-studies (DIVE, DIVE2)-protocols. BMJ Open Respir Res 12:e003750. https:\/\/doi.org\/10.1136\/bmjresp-2025-003750","journal-title":"BMJ Open Respir Res"},{"key":"9204_CR134","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s41030-025-00322-1","volume":"12","author":"SP Bhatt","year":"2026","unstructured":"Bhatt SP, Freemantle N, Soliman M, Heble J, Cabon Y, Mayen Herrera E et al (2026) Dupilumab Versus Mepolizumab for COPD: Evaluating Efficacy Outcomes Using Placebo-Adjusted Indirect Treatment Comparison. Pulm Ther 12:201\u2013217. https:\/\/doi.org\/10.1007\/s41030-025-00322-1","journal-title":"Pulm Ther"},{"key":"9204_CR135","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40265-026-02303-3","volume":"86","author":"M Cazzola","year":"2026","unstructured":"Cazzola M, Bajpai J, Calzetta L, Matera MG, Rogliani P (2026) GOLD 2026: Transforming COPD Management with Early Intervention, Multi-dimensional Assessment, and Personalized Care. Drugs 86:581\u2013597. https:\/\/doi.org\/10.1007\/s40265-026-02303-3","journal-title":"Drugs"},{"key":"9204_CR136","doi-asserted-by":"publisher","first-page":"e12091","DOI":"10.1002\/clt2.12091","volume":"11","author":"M Suzuki","year":"2021","unstructured":"Suzuki M, Cole JJ, Konno S, Makita H, Kimura H, Nishimura M et al (2021) Large-scale plasma proteomics can reveal distinct endotypes in chronic obstructive pulmonary disease and severe asthma. Clin Transl Allergy 11:e12091. https:\/\/doi.org\/10.1002\/clt2.12091","journal-title":"Clin Transl Allergy"},{"key":"9204_CR137","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2147\/ITT.S532291","volume":"14","author":"E Quek","year":"2025","unstructured":"Quek E, Horn N, Siddiqui S (2025) Precision Medicine in Asthma: The Role of Biomarkers. Immunotargets Ther 14:1479\u20131513. https:\/\/doi.org\/10.2147\/ITT.S532291","journal-title":"Immunotargets Ther"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09204-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-026-09204-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09204-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:41:50Z","timestamp":1790257310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-026-09204-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":137,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9204"],"URL":"https:\/\/doi.org\/10.1007\/s12016-026-09204-z","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"24 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given that all authors are native Chinese speakers, partial text of the manuscript was first written in Chinese and translated into English via Doubao and DeepSeek AI tools. The authors have carefully checked and modified the translated content, and bear ultimate responsibility for the entire manuscript.","order":2,"name":"Ethics","label":"Declaration of Generative AI in Scientific Writing","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All illustrations and figures presented in this study are original and independently produced by the first author Cong Xie via Adobe Illustrator software. No generative artificial intelligence or automated drawing tools were involved throughout the figure preparation process.","order":3,"name":"Ethics","label":"Declaration of Preparing Figures","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"80"}}